Key result
Contemporary transcatheter aortic valve platforms achieved comparable early adjusted severe prosthesis-patient mismatch rates of 1.6% to 2.7% with no significant differences between the SAPIEN 3 Ultra Resilia, Evolut FX, and Navitor groups in patients with extremely small annuli.
Why the study?
Does TAVR using contemporary SA-SEV or IA-SEV improve severe prosthesis-patient mismatch compared to BEV in older Japanese patients with extremely small aortic annuli?
Does TAVR using contemporary SA-SEV or IA-SEV improve severe prosthesis-patient mismatch compared to BEV in older Japanese patients with extremely small aortic annuli?
Answers are grounded in this paper and cite their sources.
Contemporary BEV, SA-SEV, and IA-SEV TAVR platforms achieve comparable early hemodynamic outcomes and low PPM rates in challenging anatomy of extremely small aortic annuli.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shek et al. (2026) conducted an editorial in Severe aortic stenosis with extremely small aortic annuli (n=385). Contemporary transcatheter aortic valve platforms (SAPIEN 3 Ultra Resilia, Evolut FX, and Navitor) vs. Compared against each other (BEV, SA-SEV, IA-SEV) was evaluated on Adjusted severe prosthesis-patient mismatch (PPM). Contemporary transcatheter aortic valve platforms achieved comparable early adjusted severe prosthesis-patient mismatch rates of 1.6% to 2.7% with no significant differences between the SAPIEN 3 Ultra Resilia, Evolut FX, and Navitor groups in patients with extremely small annuli.
Synapse has enriched 10 related papers. Consider them for comparative context: